abstract |
The present invent tion relates to compounds of Formula (I): wherein R2, R3, R4, R9, Ar, UC, X, Y, Q, n and p are as defined in the specification. The compounds are useful as CCR-3 receptor antagonists, and therefore, may be used for treatment of CCR-3 mediaed diseases. |